About Exonics
Exonics is a company based in Boston (United States) founded in 2016 was acquired by Vertex Pharmaceuticals in June 2019.. Exonics has raised $67.04 million across 3 funding rounds from investors including Vertex Pharmaceuticals, The Column Group and CureDuchenne. Exonics operates in a competitive market with competitors including Alnylam, Denali Therapeutics, Ultragenyx, Beam Therapeutics and Poseida Therapeutics, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$67.04 M (USD)
in 3 rounds
-
Latest Funding Round
$22.04 M (USD), Series A
Nov 17, 2018
-
Investors
Vertex Pharmaceuticals
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Vertex Pharmaceuticals
(Jun 06, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Exonics
Exonics has successfully raised a total of $67.04M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $22.04 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $22.0M
-
First Round
First Round
(26 Feb 2017)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2018 | Amount | Series A - Exonics | Valuation |
investors |
|
| Nov, 2017 | Amount | Series A - Exonics | Valuation | TCG |
|
| Feb, 2017 | Amount | Seed - Exonics | Valuation | CureDuchenne |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Exonics
Exonics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Vertex Pharmaceuticals, The Column Group and CureDuchenne. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US life science startups are focused on.
|
Founded Year | Domain | Location | |
|
Nonprofit organization funding research and providing support for Duchenne patients.
|
Founded Year | Domain | Location | |
|
Developer of drugs for the treatment of multiple disorders
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Exonics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Exonics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Exonics Comparisons
Competitors of Exonics
Exonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Denali Therapeutics, Ultragenyx, Beam Therapeutics and Poseida Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Exonics
Frequently Asked Questions about Exonics
When was Exonics founded?
Exonics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Exonics located?
Exonics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Exonics a funded company?
Exonics is a funded company, having raised a total of $67.04M across 3 funding rounds to date. The company's 1st funding round was a Seed of $5M, raised on Feb 26, 2017.
What does Exonics do?
Exonics was founded in 2016 as a biotech spin-out from the University of Texas Southwestern Medical Center, focusing on gene editing for rare diseases. CRISPRCas-9 technologies are utilized to target Duchenne Muscular Dystrophy mutations, with AAV delivery tested in mouse models showing dystrophin restoration. Seed funding of 5 million was secured in 2017 from CureDuchenne Ventures. Operations are based in Boston, United States.
Who are the top competitors of Exonics?
Exonics's top competitors include Juno Therapeutics, Alnylam and BioMarin Pharmaceutical.
Who are Exonics's investors?
Exonics has 3 investors. Key investors include Vertex Pharmaceuticals, The Column Group, and CureDuchenne.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.